Merck & Co., Inc. vs Tilray Brands Inc — how do they compare? Merck & Co., Inc. trades at $130.24 (market cap $321.77B), while Tilray Brands Inc trades at $4.78 (market cap $649.42M). The key difference: Merck & Co., Inc. is far larger — about 495.5× Tilray Brands Inc's market cap, and Merck & Co., Inc. pays a 2.61% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals.
| MRK | TLRY | |
|---|---|---|
Market Cap | $321.77B | $649.42M |
Sector | Health | Health |
52-Week High | $131.84 | $21.00 |
52-Week Low | $77.60 | $3.88 |
Enterprise Value | $368.53B | $816.55M |
Dividend Yield | 2.61% | — |
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.
The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →